Acute Hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction:: The ECLIPSE international, multicenter, randomized, placebo-controlled trial

被引：6
|
作者：
Udelson, James E. [1 ]
Orlandi, Cesare [2 ]
Ouyang, John [2 ]
Krasa, Holly [2 ]
Zimmer, Christopher A. [2 ]
Frivold, Geir [3 ]
Haught, W. Herbert [4 ]
Meymandi, Sheba [5 ]
Wedge, Patricia [6 ]
Konstam, Marvin M. [1 ]
Gheorghiade, Mihai [7 ]
机构：
[1] Tufts Univ New England Med Ctr, Boston, MA USA
[2] Otsuka Amer Pharmaceut Inc, Rockville, MD USA
[3] VA Loma Linda Healthcare Syst, Loma Linda, CA USA
[4] Ctr Head, Huntsville, AL USA
[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[6] Cardiovasc Clin Trials, Boston, MA USA
[7] Northwestern Univ, Sch Med, Chicago, IL 60611 USA
来源：
JOURNAL OF CARDIAC FAILURE | 2007年 / 13卷 / 09期
关键词：
D O I：
10.1016/j.cardfail.2007.10.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：793 / 794
页数：2
相关论文
共 50 条
  • [41] ACUTE HEMODYNAMIC-EFFECTS AND PHARMACOKINETICS OF RAMIPRIL IN PATIENTS WITH HEART-FAILURE - A PLACEBO-CONTROLLED 3-DOSE STUDY
    BEERMANN, B
    NYQUIST, O
    HOGLUND, C
    JACOBSSON, KA
    NASLUND, U
    JENSENURSTAD, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 45 (03) : 241 - 246
  • [42] Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER)
    Asakura, Masanori
    Yamamoto, Haruko
    Asai, Kuniya
    Hanatani, Akihisa
    Hirata, Ken-ichi
    Hirayakma, Atsushi
    Kimura, Kazuo
    Kobayashi, Youichi
    Momomura, Shin-ichi
    Nakagawa, Yoshihisa
    Nishi, Yutaro
    Saito, Yoshihiko
    Satoh, Yasuhiro
    Yamada, Takahisa
    Yamashina, Akira
    Yasuda, Satoshi
    Yoshikawa, Tsutomu
    Kada, Akiko
    Uesaka, Hiroyuki
    Kitakaze, Masafumi
    CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (02) : 179 - 185
  • [43] Prevention of renal dysfunction with hypertonic saline solution in patients with decompensated heart failure: a prospective, double blind, randomized, placebo-controlled trial
    Issa, V.
    Ayub-Ferreira, S. M.
    Bacal, F.
    Guimaraes, G. V.
    Andrade, L.
    De Braganca, A. C.
    Conceicao-Souza, G. E.
    Chizzola, P. R.
    Velasco, I. T.
    Bocchi, E. A.
    EUROPEAN HEART JOURNAL, 2011, 32 : 162 - 163
  • [44] Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: A randomized double-blinded placebo-controlled study
    Doehner, Wolfram
    Todorovic, Johanna
    Kennecke, Cornelia
    Rauchhaus, Mathias
    Sandek, Anja
    Lainscak, Mitja
    van Linthout, Sophie
    Tschoepe, Carsten
    von Haehling, Stephan
    Anker, Stefan D.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 161 (03) : 137 - 142
  • [45] Hemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist in patients with advanced heart failure
    Udelson, JE
    Smith, WB
    Hendrix, GH
    Painchaud, CA
    Ghazzi, MM
    Thomas, I
    Ghali, JK
    Selaru, P
    Pressler, ML
    Konstam, MA
    CIRCULATION, 2000, 102 (18) : 593 - 593
  • [46] Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial
    Bislev, Lise Sofie
    Rodbro, Lene Langagergaard
    Bech, Jesper Norgaard
    Pedersen, Erling Bjerregaard
    Rolighed, Lars
    Sikjaer, Tanja
    Rejnmark, Lars
    CLINICAL ENDOCRINOLOGY, 2018, 89 (05) : 656 - 666
  • [47] Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure - A randomized, double-blind, placebo-controlled trial
    Ponikowski, Piotr
    Anker, Stefan D.
    Szachniewicz, Joanna
    Okonko, Darlington
    Ledwidge, Mark
    Zymlmski, Robert
    Ryan, Enda
    Wasserman, Scott M.
    Baker, Nigel
    Rosser, Dylan
    Rosen, Stuart D.
    Poole-Wilson, Philip A.
    Banasiak, Waldemar
    Coats, Andrew J. S.
    McDonald, Ken
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (07) : 753 - 762
  • [48] Prognostic effect of a vasopressin V2 receptor antagonist in acute congestive heart failure patients with hypoperfusion, the wet-cold pattern
    Matsushita, Kenichi
    Harada, Kazumasa
    Miyamoto, Takamichi
    Iida, Kiyoshi
    Yamamoto, Yoshiya
    Shiraishi, Yasuyuki
    Nagatomo, Yuji
    Yoshino, Hideaki
    Yamamoto, Takeshi
    Nagao, Ken
    Takayama, Morimasa
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (11) : 1795 - 1805
  • [49] Effects of tolvaptan (OPC-41061), a vasopressin V2 receptor antagonist, and furosemide on hemodynamics, renal functions, serum electrolytes, and neurohormones in dogs with and without heart failure
    Onogawa, T
    Yamamura, Y
    Nakamura, S
    Nakayama, S
    Fujiki, H
    Mori, T
    CIRCULATION, 2004, 110 (17) : 21 - 21
  • [50] EFFECTS OF SATAVAPTAN, AN ORAL VASOPRESSIN V2 RECEPTOR ANTAGONIST, ON MANAGEMENT OF ASCITES AND MORBIDITY IN LIVER CIRRHOSIS IN A LONG-TERM, PLACEBO-CONTROLLED STUDY
    Wong, F.
    Bernardi, M.
    Horsmans, Y.
    Cabrijan, Z.
    Watson, H.
    Gines, P.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S42 - S43
12345